Evidence map›Paper›PMID 26056335›Full record

ArticleHypertension (Dallas, Tex. : 1979)2015

Adiposity, obesity, and arterial aging: longitudinal study of aortic stiffness in the Whitehall II cohort.

Eric J Brunner, Martin J Shipley, Sara Ahmadi-Abhari, Adam G Tabak, Carmel M McEniery, Ian B Wilkinson, Michael G Marmot, Archana Singh-Manoux, Mika Kivimaki

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 109 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Eric J BrunnerFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.). e.brunner@ucl.ac.uk.
Martin J ShipleyFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Sara Ahmadi-AbhariFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Adam G TabakFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Carmel M McEnieryFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Ian B WilkinsonFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Michael G MarmotFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Archana Singh-ManouxFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Mika KivimakiFrom the UCL Research Department of Epidemiology and Public Health, London, United Kingdom (E.J.B., M.J.S., S.A.-A., A.G.T., C.M.M., M.G.M., A.S.-M., M.K.); Semmelweis University Faculty of Medicine, 1st Department of Medicine, Budapest, Hungary (A.G.T.); Clinical Pharmacology Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom (C.M.M., J.B.W.); INSERM, Centre for Research in Epidemiology & Public Health, Hôpital Paul Brousse, Bâtiment, France (A.S.-M.).
Semmelweis University · HU

Funding

Socio-economic status and heterogeneity in agingR01AG013196 · NIA · UNIVERSITY OF LONDON INST OF NEUROLOGY · PI MARMOT, MICHAEL G, SINGH-MANOUX, ARCHANA · 1996 to 2013
$3.5M
Socioeconomic gradient in CHD in early old ageR01HL036310 · NHLBI · UNIVERSITY OF LONDON · PI KIVIMAKI, MIKA J, MARMOT, MICHAEL G · 1986 to 2012
$3.1M
Health behaviors over the adult lifecourse and cognitive agingR01AG034454 · NIA · UNIVERSITY COLLEGE LONDON · PI KIVIMAKI, MIKA J, SINGH-MANOUX, ARCHANA · 2009 to 2013
$1.5M
British Heart Foundation FS/12/8/29377British Heart Foundation PG/11/63/29011British Heart Foundation RG/07/008/23674British Heart Foundation RG/13/2/30098Department of HealthMedical Research Council G0100222Medical Research Council G0601647Medical Research Council G0701830Medical Research Council G0902037Medical Research Council G1000616Medical Research Council G19/35Medical Research Council G8802774Medical Research Council K013351Medical Research Council MR/K013351/1NHLBI NIH HHS R01HL036310NIA NIH HHS R01AG013196NIA NIH HHS R01AG034454
6 · The paper itself

Abstract

We sought to determine whether adiposity in later midlife is an independent predictor of accelerated stiffening of the aorta. Whitehall II study participants (3789 men; 1383 women) underwent carotid-femoral applanation tonometry at the mean age of 66 and again 4 years later. General adiposity by body mass index, central adiposity by waist circumference and waist:hip ratio, and fat mass percent by body impedance were assessed 5 years before and at baseline. In linear mixed models adjusted for age, sex, ethnicity, and mean arterial pressure, all adiposity measures were associated with aortic stiffening measured as increase in pulse wave velocity (PWV) between baseline and follow-up. The associations were similar in the metabolically healthy and unhealthy, according to Adult Treatment Panel-III criteria excluding waist circumference. C-reactive protein and interleukin-6 levels accounted for part of the longitudinal association between adiposity and PWV change. Adjusting for chronic disease, antihypertensive medication and risk factors, standardized effects of general and central adiposity and fat mass percent on PWV increase (m/s) were similar (0.14, 95% confidence interval: 0.05-0.24, P=0.003; 0.17, 0.08-0.27, P<0.001; 0.14, 0.05-0.22, P=0.002, respectively). Previous adiposity was associated with aortic stiffening independent of change in adiposity, glycaemia, and lipid levels across PWV assessments. We estimated that the body mass index-linked PWV increase will account for 12% of the projected increase in cardiovascular risk because of high body mass index. General and central adiposity in later midlife were strong independent predictors of aortic stiffening. Our findings suggest that adiposity is an important and potentially modifiable determinant of arterial aging.

Indexed as

AdiposityAdultAgingBody Mass IndexCohort StudiesC-Reactive ProteinFemaleHumansInterleukin-6LondonLongitudinal StudiesMaleMiddle AgedObesityPredictive Value of TestsPulse Wave AnalysisC-Reactive ProteinInterleukin-6agingarterial stiffnessepidemiologylongitudinal studiesobesity

Identifiers

PMID26056335
PMCPMC4490910
OpenAlexW1921418515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.